Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GOT1 | P17174 | 5/20 | 0.41 |
| ▸ | C5AR1 | P21730 | 7/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.34 |
| ▸ | BRD2 | P25440 | 1/20 | 0.34 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.34 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9982697 | 0.92 | GOT1 (0.39) | GOT1C5AR1OPRM1OPRL1OPRK1 | |
| SCHEMBL12069834 | 0.92 | OPRM1 (0.38) | GOT1C5AR1OPRM1OPRL1OPRK1 | |
| SCHEMBL12069193 | 0.91 | OPRM1 (0.42) | GOT1C5AR1OPRM1OPRL1OPRK1 | |
| SCHEMBL14814879 | 0.90 | GOT1 (0.38) | GOT1C5AR1OPRM1OPRL1OPRK1 | |
| SCHEMBL14814877 | 0.90 | GOT1 (0.38) | GOT1C5AR1OPRM1OPRL1OPRK1 | |
| SCHEMBL12069192 | 0.90 | DRD2 (0.40) | GOT1C5AR1OPRM1OPRL1OPRK1 | |
| SCHEMBL12067252 | 0.89 | TRPV1 (0.42) | GOT1C5AR1OPRM1OPRL1OPRK1 | |
| SCHEMBL12067251 | 0.89 | GOT1 (0.39) | GOT1C5AR1OPRM1OPRL1OPRK1 | |
| SCHEMBL12067691 | 0.87 | C5AR1 (0.47) | C5AR1OPRM1MAPT | |
| SCHEMBL9982729 | 0.85 | C5AR1 (0.41) | C5AR1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582681-A1 | PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | Novartis AG (CH) | 2013-04-24 | — | — | EP | disclosed |
| US-20130085161-A1 | PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2013-04-04 | — | — | US | disclosed |
| US-20130085161-A1 | PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2013-04-04 | — | — | US | disclosed |
| WO-2011157793-A1 | PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011157793-A1 | PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085161-A1 | PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | IGF1R, IGFBP1, IGFBP2 | GOT1 539/4885C5AR1 1212/4885OPRM1 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.